Studies of oncogenes and tumor-suppressor genes in human thyroid carcinomas, and their clinical implications

Langenbeck's Archives of Surgery

Volumn 384, Issue 1, 1999, Pages 1-8

  Goretzki, Peter E ^a   Dotzenrath, Cornelia ^a   Simon, Dietmar ^a   Röher, Hans Dietrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Oncogene; Thyroid carcinoma; Tumor suppressor gene

Indexed keywords

DNA; IODINE; MESSENGER RNA;

ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

CARCINOGENS; GENES, TUMOR SUPPRESSOR; HUMANS; THYROID NEOPLASMS;

EID: 0032905245     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050166     Document Type: Review

References (97)

1. Grant C, Hay IA, Gough I, et al. (1988) Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery 104: 954-962
2. Rüter A, Nishiyama R, Lennquist S (1997) Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg 21: 15
3. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338:297
4. Goretzki PE, Frilling A, Simon D, et al. (1990) Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 118:48-63
5. Bäckdahl M, Carstensen J, Auer G, et al. (1986) Statistical evaluation of the prognostic value of nuclear DNA content in papillary, follicular, and medullary thyroid tumors. World J Surg 10:974-980
6. Grant CS, Hay ID, Ryan JJ, et al. (1990) Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. World J Surg 14:283-289
7. Schelfhout LJDM, Cornelisse CJ, Goslings BM, et al. (1990) Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms. Int J Cancer 45: 16-20
8. Zedenius J, Auer O, Bäckdahl M, et al. (1992) Follicular tumors of the thyroid gland: diagnosis, clinical aspects and nuclear DNA analysis. World J Surg 16:589
9. Jenkins RB, Hay ID, Herath JF, et al. (1990) Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer 66: 1213
10. Bondeson L, Bengtsson A, Bondeson AG, et al. (1989) Chromosome studies in thyroid neoplasia. Cancer 64:680
11. Herrmann ME, Talpos GB, Mohamed AN, et al. (1991) Genetic markers in thyroid tumors. Surgery 110:941
12. Zedenius J, Wallin G, Svensson A, et al. (1995) Deletions of the long arm of chromosome 10 in progression of follicular thyroid tumors. In: Zedenius J. (ed) Molecular genetic alterations in human thyroid tumor. Repro Print AB, Stockholm, pp 50
13. Marsh DJ, Eheng Z, Zedenius J, et al. (1997) Differential loss of heterozygosity in the region of the cowden locus within 10q22-23 in follicular thyroid adenomas and carcinomas. Cancer 57:500
14. Ward LS, Brenta G, Medvedovic M, et al. (1998) Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. J Clin Endocrinol Metab 83:525
15. Zedenius J, Wallin G, Svensson A, et al. (1995) Allelotyping of follicular thyroid tumors. Hum Genet 96:27
16. Herrmann ME, Mohamed A, Talpos G, et al. (1991) Cytogenetic study of a papillary thyroid carcinoma with a rearranged chromosome 10. Cancer Genet Cytogenet 57:209
17. Wright PA, Lemoine NR, Goretzki P, et al. (1991) Mutations of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6: 1693
18. Lemoine NR, Mayall ES, Wyllie FS, et al. (1989) High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 4: 159
19. Namba H, Rubin SA, Fagin JA (1990) Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474
20. Wright PA, Williams ED, Lemoine NR, et al. (1991) Radiation-associated and spontaneous human thyroid carcinomas show different pattern of ras oncogene mutation. Oncogene 6:471
21. Clark OH, Gerend PL, Goretzki P, et al. (1983) Characterization of the thyrotropin receptor-adenylate cyclase system in neoplastic human thyroid tissue. J Clin Endocrinol Metab 57: 140
22. Roger P, Taton M, vanSande J, et al. (1988) Mitogenic effect of thyrotropin and adenosine 3′5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 66: 1158
23. Ledent C, Parmentier M, Maenhaut C, et al. (1991) The TSH cyclic AMP cascade in the control of thyroid cell proliferation: the story of a concept. Thyroidology 3:97
24. Maenhaut C, Roger PP, Reuse S, et al. (1991) Activation of the cyclic AMP cascade as an oncogenic mechanism: the thyroid example. Biochemie 73:29
25. Parmentier M, Libert F, Maenhaut C, et al. (1989) Molecular cloning of the thyrotropin receptor. Science 246: 1620
26. Bourne HR, Sanders DA, McCormick F (1990) The GTPase superfamily: a conserved switch for diverse cell functions. Nature 348: 125
27. Parma J, Duprez L, VanSande J, et al. (1993) Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649
28. Kopp P, VanSande J, Parma J, et al. (1995) Congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 332: 150
29. Paschke R, Tonacchera M, VanSande J, et al. (1994) Identification and functional characterizatioon of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid. J Clin Endocrinol Metab79: 1785
30. Lyons J, Landis CA, Harsh G, et al. (1990) Two G protein oncogenes in human endocrine tumors. Science 249:655
31. Goretzki PE, Lyons J, Stacy-Philips S, et al. (1992) Mutational activation of ras and gsp oncogenes in differentiated thyroid cancer and their biological implications. World J Surg 16:576
32. Suarez HG, Villard JA, Caillou B, et al. (1991) GSP mutations in human thyroid tumours. Oncogene 6:667
33. Gorelov VN, Gyenes M, Neser F, et al. (1996) Distribution of Gs-alpha activating mutations in human thyroid tumors mesured by subcloning. J Cancer Res Clin Oncol 122:453
34. Goretzki PE, Gorelov V, Weißmann K, et al. (1993) Mutation and expression of alpha Gs in differentiated thyroid carcinoma (DTC) and medullary thyroid carcinoma (MTC). Exp Clin Endocrinol 101:54
35. Ringel MD, Saji M, Schwindinger WF, et al. (1998) Absence of activating mutations of the genes encoding the alpha subunits of G11 and Gq in thyroid neoplasia. J Clin Endorinol Metab 83:554
36. Spambalg D, Sharifi N, Elisei R, et al. (1996) Structural studies of the thyrotropin receptor and Gs-alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation. J Clin Endocrinol Metab 81:3898
37. Waldmann V, Rabes HM, et al. (1997) Absence of Gs-alpha gene mutations in childhood thyroid tumors after Chernobyl in contrast to sporadic adult thyroid neoplasia. Cancer 57:2358
38. Kitahori Y, Naitoh H, Konishi N, et al. (1997) Genetic alterations in N-bis(2-hydroxypropyl)nitrosamine-induced rat transplantable thyroid carcinoma lines: analysis of the TSH-R, G-alpha-s, ras and p53 genes. Carcinogenesis 18:265
39. Burns JS, Blaydes JP, Wright PA, et al. (1992) Stepwise transformation of primary thyroid epithelial cells ba a mutant Ha-ras oncogene: an in vitro model of tumor progression. Mol Carcinog 6: 129
40. Fogelfeld L, Merchant PS, Zitman R, et al. (1993) Prevalence of K-ras point mutations in radiation-induced thyroid cancer (abstract). 67th American Thyroid Association meeting, Tampa Florida 1993, abstract 66
41. Lemoine NR, Hughes CM, Gullick WJ, et al. (1991) Abnormalities of the EGF receptor system in human thyroid neoplasia. Int J Cancer 49:558
42. Haugen DRF, Akslen LA, Varhaug JE, et al. (1992) Expression of c-erbB-2 protein in papillary thyroid carcinoma. Br J Cancer 65:832
43. DiRenzo MF, Narsimhan RP, Olivero M, et al. (1991) Expression of the met/HGF receptor in normal and neo-plastic human tissues. Oncogene 6: 1997
44. DiRenzo MF, Olivero M, Serini G, et al. (1995) Overexpression of the c-MET/HGF-receptor in human thyroid carcinomas derived from the follicular epithelium. J Endocrinol Invest 18: 134
45. Belfiori A, Constantino A, Gangemi P, et al. (1996) Low/absent Met/HGF-R expression in papillary thyroid carcinoma: a prognostic factor for distant metastasis. J Endocrinol Invest 19:57
46. Schulte KM, Antoch G, Ellrichmann M, et al. (1998) Regulation of the HGF-receptor (c-met) in the thyroid gland. Exp Clin Endocrinol Diabetes 106: 310
47. Duh QY, Gum ET, Gerend PL (1985) Epidermal growth factor receptors in normal and neoplastic thyroid tissue. Surgery 98: 1000
48. Simon D, Goretzki PE, Röher HD (1993) The significance of c-neu and p53 in endocrine tumors. Langenbecks Arch Chir - Chir Forum [Suppl 69]
49. Auguste LJ, Masood S, Westerband A, et al. (1992) Oncogene expression in follicular neoplasms of the thyroid. Am J Surg 164:592
50. Donghi R, Sozzi G, Pierotti MA, et al. (1989) The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10q11-q12 in the same region as the multiple endocrine neoplasia type 2A (MEN2A). Oncogene 4:321
51. Bongarzone I, Pierotti MA, Monzini N. et al. (1989) High frequency of activation of the tyrosine oncogenes in human papillary thyroid carcinoma. Oncogene 4: 1457
52. Grieco M, Santoro M, Berlingieri MT, et al. (1990) PTC is novel rearranged from the the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557
53. Santoro M, Carlomagno F, Hay I, et al. (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89: 1517
54. Zou M, Shi Y, Farid NR (1994) Low rate of ret proto-oncogene activation (PTC/ret-PTC) in papillary thyroid carcinomas from Saudi Arabia. Cancer 73: 176
55. Mayr B, Potter E, Goretzki P, et al. (1998) Expression of RET/PTC 1, -2, -d3, and -4 in German papillary thyroid carcinoma. Br J Cancer 77:903
56. Bounacer A, Wicker R, Caillou B, et al. (1997) High prevalence of activating ret proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. Oncogene 15: 1263
57. Klugbauer S, Demidchik EP, Lengtelder E, et al. (1998) Molecular analysis of new subtypes of ELE/RET rearrangements, their reciprocal transcripts and breakpoints in papillary carcinoma of children after Chernobyl. Oncogene 16:671
58. Tallini G, Santoro M, Helie M, et al. (1998) Ret/PTC oncogene activation defines a subset of papillary thyroid carcinoma lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 4:287
59. Sugg SL, Zheng L, Rosen IB, et al. (1996) RET/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinoma: implications of metastatic potential? J Clin Endocrinol Metab 81:3360
60. Mayr B, Brabant G, Goretzki P, et al. (1997) Ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab 82: 1306
61. Nikiforov YE, Rowland JM, Bove KE, et al. (1997) Distinct pattern of ret oncogene rearrangement in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57: 1690
62. Bongarzone I, Vigneri P, Mariani L, et al. (1998) RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinopathological features. Clin Cancer Res 4:232
63. Santoro M, Chiapetta G, Cerrato A, et al. (1996) Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/ PTC1 oncogene in transgenic mice. Oncogene 12: 1821
64. Mulligan LM, Kwok JBJ, Healey CS, et al. (1993) Germ-line mutations of the ret proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458
65. Lips CJM, Landsvater RM, Höppener JWM, et al. (1994) Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331:828
66. Röher HD, Simon D, Goretzki PE, et al. (1995) Die prophylaktische Radikaloperation des C-Zell-Carcinoms beim MEN-2-Syndrom auf der Grundlage des genetischen Screening. Chirurg 66: 1196
67. Wells SA, Chi DD, Toshima K, et al. (1994) Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia 2A. Ann Surg 3:327
68. Dralle H, Gimm O, Simon D, et al. (1998) Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22: 1744
69. Goretzki P, Hoppner W, Clark OH, et al. (1998) Genetic and bichemical screening for endocrine diseases. World J Surg 22:(in press)
70. Lips CJM, Moers AMJ, Landsvater RM, et al. (1998) Clinical relevance of the molecular diagnosis in multiple endocrine neoplasia type 2: genotype-phenotype correlations. Cancer Res Clin Oncol 124[Suppl]: 17
71. Zedenius J, Wallin G, Hamberger B, et al. (1994) Somatic and MEN 2A de novo mutations ifentified in the retprotooncogene by screening of sporadic MTCs. Hum Mol Genet 3: 1259
72. Frank-Raue K, Hoppner W, Buhr H, et al. (1997) Mutationen des ret-Proto-oncogens bei medullärem Schilddrüsenkarzinom. Dtsch Med Wochenschr 122: 143
73. Nakamura T, Yana I, Kobayashi T, et al. (1992) p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn J Cancer Res 83: 1293
74. Ito T, Seymama T, Mizuno T, et al. (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52: 1369
75. Fagin JA, Matsuo K, Karmakar A, et al. (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91: 179
76. Zou M, Shi Y, Farid NR (1993) p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 77: 1054
77. Simon D, Goretzki PE, Gorelov V, et al. (1994) Significance of p53 in human thyroid tumors. World J Surg 18:535
78. Herrmann M, Baunoch DA, Maliarik M, et al. (1995) p53 gene alterations in differentiated thyroid cancers. Oncol Rep 2:741
79. Fogelfeld L, Bauer TK, Schneider AB, et al. (1996) p53 gene mutations in radiation-induced thyroid cancer. J Clin Endocrinol Metab 81:3039
80. Hillebrandt S, Streffer C, Reiners C, et al. (1996) Mutations in the p53 tumour suppressor gene in thyroid tumours of children from areas contaminated by the Chernobyl accident. Int J Radiat Biol 69:39
81. Jones CJ, Shaw JJ, Wyllie FS, et al. (1996) High frequency deletion of the tumor suppressor ene p16INK4a (MTS1) in human thyroid cancer cell lines. Mol Cell Endocrinol 16: 115
82. Schulte KM, Niederacher D, An HX, et al. (1996) INT-2 gene amplification in differentiated human thyroid cancer. Exp Clin Endocrinol Diabetes 104: 101
83. Schulte KM, Staudt S, Niederacher D, et al. (1997) Loss of heterozygozcity for MTS2 (p15) is rare in human thyroid malignancy cancer. Thyroid 7:682
84. Zhang SY, Klein-Szanto AJP, Sauter ER, et al. (1994) Higher frequency of alterations in the 16/CDNKN2 gene in squamos cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050
85. Goretzki PE, Gorelov V, Dotzenrath C, et al. (1996) A frequent mutation/ polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer. Surgery 120: 1081
86. Smanik PA, Liu Q, Furminger TL, et al. (1997) Cloning of human sodium/iodide transporter and mechanism of the loss of radioiodine uptake activity in thyroid tumors. Thyroid 7:312 (A)
87. Köhrle J, Schmutzler C (1998) Wie kommt Jod in die Schilddrüse? Internist 39:560
88. Smanik P, Ryu KY, Theil K, et al. (1997) Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138:3555
89. Kim HK, Park HJ, Hong SJ, et al. (1997) Sodium-iodide symporter mRNA measurements by RT-PCR in thyroid tumors. Thyroid 7:47 (A)
90. Levy O, Dai G, Riedel C, et al. (1997) Characterization of the thyroid Na+/ 1-symporter with an anti-COOH terminus antibody. Biochem 94:556
91. Yoshida A, Sasaki N, Mori A, et al. (1997) Different electrophysiological character of I-,ClO4-and SCN-in the transport by Na+/I-symporter. Biochem Biophys Res Commun 231:731
92. Zhang XK, Wills KM, Husmann M, et al. (1991) Novel pathway for thyroid hormone receptor action through interaction with jun and fos oncogene activities. Mol Cell Biol 11:6016
93. Schmutzler C, Brtko J, Winzer R, et al. (1998) Functional retinoid and thyroid hormone receptors in human thyroid carcinoma cell lines and tissues. Int J Cancer 76:3680
94. Simon D, Köhrle J, Reiners C, et al. (1998) Redifferentiation therapy with retinoids - a therapeutic option in advanced follicular and papillary thyroid carcinoma. World J Surg 22:569
95. Umbricht CB, Saji M, Westra WH, et al. (1997) Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 57:2144
96. Brousset P, Chaouche N, Leprat F, et al. (1997) Telomerase activity in human thyroid carcinomas originated from the follicular cells. J Clin Endocrinol Metab 82:4214
97. Haugen BR, Nawaz S, Markham N, et al. (1997) Telomerase activity in benign and malignant thyroid tumors. Thyroid 7:337